Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review

Area of Science:

• Cardiology
• Interventional Electrophysiology

Background:

• Catheter ablation is an established treatment for atrial fibrillation, reducing long-term stroke risk and mortality.
• Patients undergoing ablation face increased peri-procedural thromboembolic risk, necessitating careful management of anticoagulation.
• Current anticoagulation practices vary due to limited randomized data and the advent of novel oral anticoagulants (NOACs).

Purpose of the Study:

• To review available data on optimal peri-procedural anticoagulation strategies for patients undergoing catheter ablation for atrial fibrillation.
• To address controversies surrounding anticoagulant management, including interruption, switching, heparin bridging, and NOAC use.

Main Methods:

• Comprehensive review of existing literature and clinical data.
• Analysis of studies addressing anticoagulation management in the context of atrial fibrillation ablation.
• Discussion of various antithrombotic treatment approaches and their implications.

Main Results:

• Significant variability exists in antithrombotic strategies due to lack of randomized trials and evolving anticoagulant therapies.
• Key areas of debate include anticoagulant interruption, switching to vitamin K antagonists, heparin bridging, and timing of therapy re-initiation.
• Optimal strategies aim to maintain the thrombotic-bleeding equilibrium during the interventional procedure.

Conclusions:

• Establishing standardized, evidence-based peri-procedural anticoagulation protocols is crucial for atrial fibrillation ablation.
• Further randomized studies are needed to guide optimal antithrombotic management, particularly with novel oral anticoagulants.
• Balancing the benefits of ablation with procedural risks requires careful consideration of anticoagulation strategies.